CHOP, in collaboration with Janssen Research & Development, is conducting a study for children and young adults up to 30 years old, with relapsed or refractory precursor T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. This clinical trial is adding the study drug, daratumumab, to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT03384654". To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.
For More InformationContact Us Online
Call (267) 426-6846